Definium Therapeutics (NASDAQ:DFTX) Upgraded by Wall Street Zen to “Hold” Rating

Definium Therapeutics (NASDAQ:DFTX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

A number of other brokerages have also recently weighed in on DFTX. Stifel Nicolaus boosted their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Piper Sandler reiterated an “overweight” rating and issued a $73.00 target price (up from $48.00) on shares of Definium Therapeutics in a report on Friday. Robert W. Baird boosted their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Needham & Company LLC upped their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, June 23rd. Finally, Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $51.15.

Definium Therapeutics Price Performance

Shares of NASDAQ:DFTX opened at $43.17 on Friday. The stock has a market capitalization of $4.30 billion, a P/E ratio of -17.34 and a beta of 2.20. The business has a 50-day moving average of $33.64 and a two-hundred day moving average of $23.82. Definium Therapeutics has a fifty-two week low of $7.96 and a fifty-two week high of $49.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, equities research analysts predict that Definium Therapeutics will post -2.27 EPS for the current fiscal year.

Insider Activity at Definium Therapeutics

In related news, CFO Brandi Roberts sold 3,013 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the transaction, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 48,096 shares of company stock worth $2,165,763. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada increased its stake in Definium Therapeutics by 10.4% during the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after acquiring an additional 6,148 shares during the period. Creative Planning lifted its position in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after acquiring an additional 1,655 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Definium Therapeutics by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock worth $315,000 after acquiring an additional 2,342 shares during the period. Rhumbline Advisers grew its holdings in shares of Definium Therapeutics by 6.3% during the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after purchasing an additional 6,839 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.